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Abstract: Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of
hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow
therapeutic window, frequent difficulty maintaining the anticoagulant effect within a narrow therapeutic window, and the need for
inconvenient monitoring. Several newer oral anticoagulants have been approved for primary and secondary prevention of stroke in
patients with non-valvular atrial fibrillation. These agents have several advantages relative to warfarin therapy. As a group, these
direct oral anticoagulants (DOAC), which include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors (rivaroxaban,
apixaban, and edoxaban), are more effective than dose adjusted warfarin for prevention of all-cause stroke (including both ischemic
and  hemorrhagic  stroke),  and  have  an  overall  more  favorable  safety  profile.  Nevertheless,  an  increased  risk  of  gastrointestinal
bleeding (with the exception of apixaban), increased risk for thrombotic complication with sudden discontinuation, and inability to
accurately assess and reverse anticoagulant effect require consideration prior to therapy initiation, and pose a challenge for decision
making in acute stroke therapy.
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INTRODUCTION
Until  recently  vitamin  K  antagonists  such  as  warfarin  were  the  only  available  oral  anticoagulants  for  stroke
prevention  in  patients  with  atrial  fibrillation.  Warfarin  is  very  effective  in  preventing  stroke  in  patients  with  atrial
fibrillation  with  an  approximately  two-thirds  reduction  in  stroke  incidence  on  the  basis  of  a  meta-analysis  of  the
randomized controlled  trials  [1].  However,  it  is  often  regarded as  suboptimal  [2]  partly  due  to  its  pharmacological
properties,  which  include  unpredictable  anticoagulant  effects,  genetic  variability  in  metabolism,  multiple  drug
interactions and dietary restrictions, a narrow therapeutic window, and the resulting need for inconvenient monitoring
[3]. In addition, warfarin carries a significant risk for hemorrhagic complications including intracranial hemorrhages [4
- 6].
Since  2010,  several  novel  oral  anticoagulants  (NOAC) have  been  approved for  use  in  the  United  States  by  the
federal Food and Drug Administration (FDA) for primary and secondary prevention of stroke in patients with non-
valvular atrial fibrillation. These agents hold promise to overcome several of the limitations associated with Warfarin
therapy.  NOAC, as  a  group,  presently include the direct  thrombin inhibitor  dabigatran and the factor  Xa inhibitors
rivaroxaban, apixaban and edoxaban. While the acronym NOAC is being used to denote their novelty over warfarin,
alternate  naming such as  direct  oral  anticoagulants  (DOAC) may be preferred in  the  future,  particularly  in  light  of
expected further developments in the field of oral anticoagulants.
In the following we will provide a brief summary of the trials investigating oral DOACs for the treatment of atrial
fibrillation, advantages and disadvantages of their use over warfarin, and highlight areas of uncertainty with respect to
their use.
*  Address  correspondence  to  this  author  at  the  Department  of  Neurology,  University  of  Massachusetts  Medical  School,  55  Lake  Ave,  North,
Worcester, MA 01655, USA; Tel: (508) 334-2527; Fax: (508) 856-6778; Email: Anand.Patel@umassmemorial.org
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DIRECT THROMBIN INHIBITOR
Dabigatran
Dabigatran etexilate is a pro-drug that is rapidly converted by a serum esterase to dabigatran which is a direct and
competitive inhibitor of thrombin (factor IIa). Dabigatran has predictable pharmacokinetics allowing for a fixed dose
regimen twice daily due to its elimination half-life of 12-17 hours. Because 80% is renally  excreted, baseline renal
function  affects its  pharmacokinetics. While dabigatran  is not metabolized via the cytochrome P450 system,  several
p-glycoprotein  inhibitors  such  as  verapamil,  amiodarone,  ketoconazole,  dronedarone,  quinidine  can  decrease  its
metabolism potentially leading to increased bleeding complications related to its use, conversely rifampin can increase
its metabolism [7].
Its  clinical  efficacy  in  preventing  ischemic  stroke  among  patients  with  atrial  fibrillation  was  evaluated  in  the
Randomized Evaluation of Long-Term Anticoagulation (RE-LY) trial [8]. RE-LY was a non-inferiority trial comparing
two different doses of dabigatran (110 mg and 150 mg twice daily) to dose adjusted warfarin (goal INR 2.0-3.0) in
patients  with  atrial  fibrillation  and  at  least  one  additional  stroke  risk  factor  (previous  history  of  stroke  or  transient
ischemic attack, a left ventricular ejection fraction of ≤40%, New York Heart Association class ≥2 heart failure with
symptoms within 6 months prior to screening, and age of at least 75 years or an age of 65 to 74 years plus diabetes,
hypertension or coronary artery disease). Patients with severe valvular heart disease, who had a stroke within 14 days or
severe stroke within the 6 months prior to screening, a condition associated with increased hemorrhage risk, creatinine
clearance of < 30 ml/min, active liver disease, and pregnancy were excluded. The trial included 18113 patients with
median follow up duration of 2 years. In the following only the key results for the 150 mg dosing regimen are discussed
as the 110 mg dose has not been FDA approved in the United States.
Dabigatran, when administered at 150 mg twice a day dosing, was more effective than warfarin in reducing the
composite end point of stroke (defined as acute onset of focal neurological deficits respecting vascular territory and
categorized as ischemic, hemorrhagic or unspecified strokes and hemorrhagic transformation of the ischemic stroke was
not considered a hemorrhagic stroke) and systemic embolism (defined as acute vascular occlusion of an extremity or an
organ documented by meaning of imaging, surgery or autopsy) by almost 36% (1.11% vs. 1.69% per year; RR 0.66,
95%  CI  0.53-0.82,  P<0.001).  Importantly,  there  were  significantly  fewer  ischemic  strokes  in  patients  receiving
dabigatran as compared to warfarin (0.92% vs. 1.20% per year; RR 0.76, 95% CI 0.60-0.98, P=0.03). Along with a
reduction in the incidence of ischemic stroke, there were also fewer hemorrhagic strokes in the dabigatran group (0.10%
vs.  0.38% per year; RR 0.26, 95% CI 0.14-0.49, P<0.001). At the same time, the rate of myocardial infarction was
higher  in  patients  with  receiving  dabigatran  than  warfarin  (0.74%  vs.  0.53%  per  year,  P=0.048)  suggesting  that
dabigatran may be less effective in reducing cardiac complications than warfarin.
Major bleeding complications were similar in both the groups (3.11% per year in dabigatran groups vs. 3.36% per
year in warfarin group; RR 0.93, P=0.31). Patients receiving dabigatran had more gastrointestinal hemorrhages than
warfarin  (1.51% vs.  1.02% per  year;  RR  1.50,  95% CI  1.19-1.89,  P<0.001)  but  at  the  same  time,  life  threatening
hemorrhages  were  less  common  in  patients  receiving  dabigatran  (1.45%  vs.  1.80%  per  year;  RR  0.81,  95%  CI
0.66-0.99,  P=0.04).  There  were  fewer  major  and  minor  systemic  hemorrhages  noted  among  patients  receiving
dabigatran. The most feared complication of anticoagulant use-intracranial hemorrhage (defined as hemorrhagic stroke,
subarachnoid  hemorrhage  and  subdural  hemorrhage)-was  significantly  lower  in  the  dabigatran  as  compared  to  the
warfarin arm (0.30% vs. 0.74% per year; RR 0.40, 95% CI 0.27-0.60, P<0.001).
Overall,  dabigatran  conferred  a  net  clinical  benefit  (defined  as  a  composite  of  stroke,  systemic  embolism,
pulmonary embolism, myocardial infarction, major bleeding and death) over warfarin in the study population (6.91%
vs. 7.64% per year; RR 0.91, 95% CI 0.82-1.00, P=0.04).
Factor Xa Inhibitors
Factor Xa inhibitors act by competitively binding to active site of activated factor X and thus inhibiting factor Xa.
All factor Xa inhibitors have relatively few drug-drug interactions, except with CYP3A4 and p-glycoprotein pathway
inhibitors, which could lead to higher anticoagulation effect than expected.
Apixaban
Apixaban has a rapid oral absorption and maximum plasma concentration is achieved in about 3 hours. Its half-life
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of 12 hours requires twice a day dosing. Steady state plasma concentrations are achieved after 3 days of regular use. It is
mainly metabolized by the liver and approximately 75% are excreted in feces and the remaining 25% through kidneys
[9, 10].
Apixaban vs. Warfarin
Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) [11] was
a randomized, double blind trial comparing apixaban 5 mg twice a day dosing (2.5 mg twice a day dosing was used in
patients with two or more of the following criteria: age more than 80 years, weight less than 60 kg or serum creatinine
≥1.5) to warfarin (target INR 2.0-3.0) in patients with atrial fibrillation and one additional vascular risk factor for stroke
(age≥75 years, history of prior stroke, transient ischemic attack or systemic embolism, congestive heart failure or left
ventricular  ejection  fraction  ≤40%  and  history  of  diabetes  mellitus  or  hypertension  requiring  pharmacological
treatment)  [11].  The  trial  included  18201  patients  with  median  follow  up  of  1.8  years.
Overall,  a  significant  21%  relative  reduction  in  the  composite  endpoint  of  all-cause  stroke  (defined  as  a  focal
neurological deficits from a non-traumatic cause lasting for at least 24 hours and including ischemic, with and without
hemorrhagic transformation, hemorrhagic and unspecified strokes) and systemic embolism were noted in the apixaban
arm compared to the warfarin arm (1.27% vs. 1.60% per year; HR 0.79, 95% CI 0.66-0.95, P=0.01 for superiority). A
substantial part of the benefit was governed by a greater (almost 50% relative) reduction in the hemorrhagic stroke in
the apixaban group (0.24% vs. 0.47% per year; HR 0.51, 95% CI 0.35-0.75, P<0.001); the rate of ischemic and other
unspecified types of strokes were equal in both groups (respective 0.97 % vs. 1.05% in apixaban vs. warfarin groups per
year; HR 0.92, 95% CI 0.74-1.13, P=0.42). There was no significant difference in incidence of myocardial infarction,
deep vein thrombosis, or pulmonary embolism between treatment arms.
Importantly, major bleeding as defined by the International Society on Thrombosis and Hemostasis (ISTH) was
reduced in the apixaban group (2.13% vs. 3.09% per year; HR 0.69, 95% CI 0.60-0.80, P<0.001). Major and minor
bleeding complications as defined by Global Use of Strategies to Open Occluded Arteries (GUSTO) or Thrombolysis in
Myocardial Infarction (TIMI) criteria were also less frequent in the apixaban group (P<0.001) [12]. Importantly, there
was no significant difference in the incidence of gastrointestinal hemorrhage between groups (0.76% vs.  0.86% per
year:  HR 0.89,  95% CI  0.70-1.15,  P=0.37).  Along with  the  reduction  in  the  hemorrhagic  strokes,  there  was  also  a
reduction  in  all  intracranial  hemorrhages  (composite  of  intracerebral  hemorrhage,  subarachnoid  hemorrhage  and
subdural hemorrhage) in patients receiving apixaban (0.33% vs. 0.80%; HR 0.42, 95% CI 0.30-0.58, P<0.001). Lastly,
patients randomized to apixaban had a lower mortality (3.52% vs.  3.94% per year, P=0.047) and more frequently a
favorable net clinical outcome, defined as composite of stroke, systemic embolism, major bleeding and death from any
cause (6.13% vs. 7.20% per year; HR 0.85, 95% CI 0.78-0.92, P<0.001).
Apixaban vs. Aspirin
Aspirin use is recommended for primary and secondary stroke prevention in patients with atrial fibrillation, who are
not suitable for treatment with vitamin K antagonists due to higher risk for bleeding complications [13]. The Apixaban
vs. Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients (AVERROES) trial [14] was a double blind,
multicenter trial, designed to determine the efficacy and safety of apixaban vs. aspirin in patients with atrial fibrillation
and at least one more vascular risk factor for stroke who were not suitable to receive vitamin K antagonists. This trial
included 5599 patients.
Apixaban was more effective in preventing strokes (ischemic or hemorrhagic) and systemic embolism as compared
to  aspirin  (1.6%  vs.  3.7%  per  year,  HR  with  apixaban  0.45,  95%  CI  0.32  to  0.62;  P<0.001).  On  further  analysis,
apixaban was associated with a greater reduction in the annual incidence in ischemic strokes (1.1% vs. 3.0% per year,
HR with apixaban 0.37; 95% CI, 0.25 to 0.55; P<0.001) and there was a similar incidence in intracranial hemorrhages
(0.4% vs. 0.4% per year, HR with apixaban 0.85, 95% CI 0.38-1.90; P=0.69) as well as all hemorrhagic strokes between
groups  (0.2%  vs.  0.3%  per  year,  HR  0.67,  95%  CI  0.24-1.88;  P=0.45).  Finally,  apixaban  was  associated  with  an
increase in the annual incidence of minor bleeding complications (6.3% vs. 5.0% per year; P=0.05) but no difference in
the annual incidence of major bleeding (1.4% vs. 1.2% per year; P=0.57) and fatal bleeding complications (0.1% vs.
0.2% per year; P=0.53) as compared to aspirin. Results were overall similar in an on-treatment analysis restricted to
events occurring while patients were taking the study drug. In this analysis apixaban was associated with a greater
annual incidence of major bleeding events (1.4% vs. 0.9% per year; P=0.07).
The results of the AVERROES study have significant implications for a substantial proportion of patients who are
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not considered candidates for anticoagulation therapy and are at risk of stroke [15, 16].
Rivaroxaban
Rivaroxaban has a high oral bioavailability and is well absorbed. It has a rapid onset of action within about 2-4
hours of administration and a half-life ranging from 7-13 hours (longer half-lives are observed in elderly individuals).
Similar to apixaban it has a dual mode of excretion with approximately one third being excreted unchanged through
kidneys and two thirds metabolized by the liver to inactive metabolites [17].
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) was a non-inferiority, double blind trial comparing
rivaroxaban 20 mg once a day (or 15 mg once a day for patients with creatinine clearance of 30-49 ml/minute) to dose
adjusted warfarin in patients with non-valvular atrial fibrillation with moderate risk for stroke (defined as a CHADS2
score of ≥2) [18]. This trial enrolled 14264 patients, median duration of treatment exposure was 590 days and median
follow up duration was 707 days.
In the primary or per-protocol analysis, rivaroxaban was non-inferior to warfarin in preventing stroke (composite of
ischemic or hemorrhagic stroke) or systemic embolism (1.7% vs. 2.2% per year; HR 0.79, 95% CI 0.66-0.96, P<0.001).
The incidence of myocardial infarction (0.9% vs.1.1% per year; HR 0.81, 95% CI 0.63-1.06, P=0.12) and death (1.9%
vs. 2.2% per year; HR 0.85, 95% CI 0.70-1.02, P=0.07) was similar between groups.
There was no difference in major and non-major clinically relevant  bleeding complications between the groups
(14.9% vs. 14.5% per year; HR 1.03, 95% CI 0.96-1.11, P=0.44). However, intracranial hemorrhages (0.5% vs. 0.7%
per year; HR 0.67, 95% CI 0.47-0.93, P=0.02) and fatal bleeding complications (0.2% vs. 0.5% per year; HR 0.50, 95%
CI 0.31-0.79, P=0.003) were reduced in the rivaroxaban arm. Major gastrointestinal bleeding was more common in the
rivaroxaban arm (3.2% vs. 2.2% per year, P<0.001).
Edoxaban
Edoxaban also has relatively high oral bioavailability with quick absorption and peak plasma concentration within
1.5 hours of administration. It has a half-life of approximately 10-14 hours [19].
The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF TIMI 48) was a double blind, randomized, double-dummy, non-inferiority trial comparing
two doses (60 mg once a day in high dose group and 30 mg once a day in low dose group, the dose was halved in either
group if any of the following characteristics was present: creatinine clearance of 30 to 50 ml/minute, body weight ≤ 60
kilograms, concomitant use of verapamil or quinidine) of edoxaban to dose adjusted warfarin (goal INR 2.0-3.0) in
patients with atrial fibrillation with a moderate to high risk for stroke (defined as a CHADS2 score of ≥2) [20]. This trial
enrolled 21105 patients with median follow up duration of 2.8 years.
In the modified intention to treat analysis (population in the treatment period), there were fewer strokes or systemic
embolism in the high dose edoxaban group as compared to warfarin group (1.18% vs. 1.50% per year; HR 0.79, 95% CI
0.63-0.99, P<0.001 for non-inferiority). In the intention to treat analysis (population in the overall study period), there
was a non-significant trend in favor of high dose edoxaban in preventing stroke (composite of ischemic or hemorrhagic
stroke) or systemic embolisms (1.57% vs. 1.80% per year; HR 0.87, 95% CI 0.73-1.04, P=0.08). The overall stroke
incidence was similar between groups (1.49% per year in the high dose edoxaban vs. 1.69% per year in warfarin group;
HR 0.88, 95% CI 0.75-1.03, P=0.11). However, there was a there was a 46% relative reduction in hemorrhagic strokes
in the high dose edoxaban group (0.26% vs. 0.47% per year; HR 0.54, 95% CI 0.38-0.77, P<0.001) while the incidence
of ischemic strokes was similar between treatment arms (1.25% per year in either group; HR 1.00, 95% CI 0.83-1.19,
P=0.97). A significant 20% relative reduction in non-disabling or non-fatal strokes was noted in the high dose edoxaban
group as compared to warfarin, but the number of fatal and disabling strokes was similar between arms. The composite
major adverse cardiac events, defined as myocardial infarction, stroke, systemic embolism or death from cardiovascular
cause, were less frequent in the high dose edoxaban group (4.41% vs. 4.98% per year; HR 0.88, 95% CI 0.81-0.97,
P=0.01). The incidence of myocardial infarction remained same in both the groups (0.70% vs. 0.75% per year; HR 0.94,
95% CI 0.74-1.19, P=0.60).
There  was  a  significant  reduction  in  bleeding  complications  in  the  high  dose  edoxaban  group  including  major
bleeding (2.75% vs. 3.43% per year; HR 0.80, 95% CI 0.71-0.91, P<0.001), intracranial hemorrhages (0.39% vs. 0.85%
per year; HR 0.47, 95% CI 0.34-0.63, P<0.001), and fatal intracranial hemorrhages (0.15% vs. 0.27% per year; HR
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0.58, 95% CI 0.35-0.95, P=0.03). Conversely, a higher incidence of gastrointestinal bleeding was observed in the high
dose  edoxaban  group  (1.51%  vs.  1.23%  per  year;  HR  1.23,  95%  CI  1.02-1.50,  P=0.03).  Other  hemorrhagic
complications including fatal hemorrhages, life threatening hemorrhages, minor bleeding, clinically relevant non major
bleeding and any overt bleeding complications were significantly reduced in the high dose edoxaban group.
Summary of Doac Trials
Meta-analysis of the four above summarized DOAC-trials (RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF-
TIMI)  included  as  a  group  vs.  dose  adjusted  warfarin  for  preventing  stroke  indicated  that  high  dose  DOACs
significantly reduce the incidence of all stroke (ischemic or hemorrhagic stroke) and systemic embolism by 19% as
compared to Warfarin (RR 0.81, 95% CI 0.73-0.91, P<0.0001) [21]. This benefit was mainly driven by a substantial
51% reduction in hemorrhagic strokes (RR 0.49, 95% CI 0.38-0.64, P<0.0001) [21].
Further,  compared  to  warfarin,  treatment  with  DOACs  was  associated  with  a  non-significant  18%-reduction  in
ischemic strokes (RR 0.92, 95% CI 0.83-1.02, P=0.1) and a similar incidence of myocardial infarction (RR 0.97, 95%
CI 0.78-1.20, P=0.77). DOACs use was associated with a reduction in all-cause mortality (RR 0.90, 95% CI 0.85-0.95,
P=0.0003).  Importantly,  DOAC-treatment  was  associated  with  a  significant  reduction  in  incident  intracranial
hemorrhages  (combination  of  hemorrhagic  stroke,  subarachnoid  hemorrhage,  subdural  hemorrhage  and  epidural
hemorrhage) (RR 0.48, 95% CI 0.39-0.59, P<0.0001) but increased risk for gastrointestinal bleeding (RR 1.25, 95% CI
1.01-1.55, P=0.043) [21]. Overall, there was no significant difference in the incidence of stroke or systemic embolism
the following subgroups as stratified by: age <75 vs. ≥75 years; sex; presence of diabetes; history of stroke or transient
ischemic attack; degree of renal impairment; CHADS2-score; time in therapeutic range; vitamin K antagonist status at
study entrance [21].
Similarly, there was no significant difference in the incidence of major bleeding complications except for the time in
therapeutic range (<66% vs. ≥66%). Specifically, there was a greater relative reduction in major bleeding complications
with  DOAC therapy,  when the  center-based  time in  the  therapeutic  range  was  <66% (RR 0.69  vs.  0.93,  P=0.022),
suggesting that efficacy and safety of DOACs is independent of how well warfarin therapy is managed and may be
particularly useful for patients whose INR is difficult to maintain [21].
When  the  meta-analysis  was  restricted  to  factor  Xa  inhibitors,  the  overall  results  were  unchanged.  Additional
sensitivity analyses indicated that low dose DOAC treatment (which is not approved by the FDA in the United States)
provided  similar  efficacy  in  preventing  stroke  and  systemic  embolism  as  compared  to  warfarin.  Though  ischemic
strokes were more frequent in this group as compared to warfarin, this effect was offset by a reduction in the incidence
of hemorrhagic strokes. Similar to higher dose DOACs, low dose DOACs were associated with a reduction in all-cause
mortality as well as similar incidence of gastrointestinal hemorrhages.
Advantages of Doac Over Warfarin Use
DOACs use does not require dietary restrictions, which is an advantage of warfarin - which may exert unstable
anticoagulation  effects  depending  on  the  amount  of  consumed  vitamin  K  and  thus  result  in  increased  risk  for
thromboembolism or hemorrhagic complications in the case of subtherapeutic and supratherapeutic levels, respectively
[22].
Furthermore, their fewer drug-drug interactions render DOACs a more suitable option for many patients with atrial
fibrillation that have multiple comorbid conditions and require taking multiple medications [23].
In addition to having fewer dietary and drug-drug interactions, DOACs are associated with a relatively steady state
plasma concentration, leading to lesser fluctuation in the anticoagulation effect that obviates the need for frequent and
regular laboratory monitoring and may contribute to observed fewer bleeding complications as compared to warfarin
[21].
DOACs have quick absorption, shorter peak time leading to quicker onset of steady state anticoagulation effect as
compared to warfarin, which requires bridging with other form of antiplatelet or anticoagulants by the time optimal
anticoagulation effect is achieved. Conversely, after discontinuation DOACs are associated with relatively quick offset
of  anticoagulant  effect  due  to  their  shorter  half-life  and  absent  need  for  resynthesis  of  the  vitamin  K  dependent
coagulation factors by the liver.
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DISADVANTAGES OVER WARFARIN USE
DOAC Reversal
In  contrast  to  warfarin,  which  can  be  relatively  quickly  reversed  with  recombinant  Factor  VIIa  (rFVIIa)  and
prothrombin  complex  concentrate  (PCC)  [24],  there  is  presently  no  effective  and  established  treatment  strategy  to
reverse the action of DOACs, which is hampered as a result of their competitive inhibition of thrombin or activated
factor X (as opposed to clotting factor deficiency).
Nevertheless, experimental data in a mouse model of ICH associated with dabigatran, PCC, but not rFVIIa or fresh
frozen plasma (FFP), prevented intracerebral hematoma expansion [25]. Conversely, in a rabbit model, rFVIIa and PCC
partially  improved  laboratory  parameters  but  failed  to  reverse  rivaroxaban  associated  bleeding  [26].  However,
rivaroxaban-related,  but  not  dabigatran-related,  coagulopathy could be reversed with PCC in a  randomized,  double
blind placebo controlled trial in healthy volunteers [26]. Clinically, emergent hemodialysis could expedite clearance of
DOACs, which are renally eliminated to a substantial degree (see above) [16]. Indeed, in patients with end-stage renal
disease, 62-68% of dabigatran was removed with hemodialysis of 4 hours duration [26]. However, this approach may
be of limited practical utility and efficacy of this approach remains to be shown. Also, hemodialysis may not effectively
removing rivaroxaban and apixaban, which are largely protein bound.
DOAC Antidotes in Development
Several  specific  antidotes  for  DOAC-reversal  are  presently  in  development  [27].  Idarucizumab,  which  is  a
humanized antibody fragment against dabigatran that has a 350 times higher affinity to thrombin than dabigatran. It has
been shown to successfully reverse the effect of dabigatran by examining clotting time in the rat [28]. The RE-VERSal
Effects of Idarucizumab on Active Dabigatran (REVERSE-AD) trial is an ongoing international study, to investigate its
role as a potential antidote in the clinical setting in patients taking dabigatran [NCT02104947].
The recombinant antidote protein PRT064445 is a modified form of factor Xa, which acts by reducing plasma anti
factor  Xa  activity  and  the  non-protein  bound  fraction  of  factor  Xa  inhibitors.  In  rabbits  treated  with  rivaroxaban,
PRT064445 restored hemostasis after  liver laceration,  showing promise as a potential  antidote to reverse factor Xa
inhibitor associated coagulopathy [29].
PER977  is  a  small,  synthetic,  water  soluble  cationic  molecule,  designed  to  bind  specifically  to  unfractionated
heparin  and low molecular  weight  heparin.  Similarly,  it  can also bind to  oral  factor  Xa inhibitors  as  well  as  direct
thrombin  inhibitors.  In  80  healthy  volunteers,  by  checking  whole  blood  clotting  time,  PER977 was  able  to  restore
baseline hemostasis from anticoagulated state (achieved with edoxaban) within 10 to 30 minutes of administration and
effect was sustained for 24 hours [30].
While these agents are promising in reversing the coagulopathy related to DOACs their clinical safety and efficacy
remains to be established.
Anticoagulation Efficacy
In  contrast  to  warfarin,  routine  laboratory  testing  with  activated  partial  thromboplastin  time  (aPTT)  and
International  normalized  ratio  (INR)  are  insensitive  to  accurately  determine  the  relative  intensity  of  DOAC  [31].
Though,  dilute  thrombin  time  (dTT),  ecarin  clotting  time  (ECT)  and  ecarin  chromogenic  assay  (ECA)  in  case  of
dabigatran  and  chromogenic  anti  Xa  assay  in  case  of  factor  Xa  inhibitors  could  be  used  to  better  quantify  the
anticoagulation effect, they are not widely available, known to have inter-lot variability, and may be challenging to
perform in a timely fashion [31].
Thrombotic Events After Sudden Discontinuation of DOACs
In light of their relatively short half-life, anticoagulant effect of DOACs is lost within 48-72 hours from the last dose
leaving  patients  at  potential  risk  for  thromboembolic  complications.  This  is  highlighted  by  the  observation  of  an
increased incidence in strokes and systemic embolic events after discontinuation of rivaroxaban as well as apixaban
while transitioning to open-label warfarin at the end of the study [32, 33]. These observations led to a boxed warning
for  all  DOACs  by  the  US  Food  and  Drug  Administration  to  avoid  sudden  discontinuation  except  in  the  setting  of
hemorrhagic  complications  or  completion  of  therapy  [33].  It  is  important  to  note  that  the  excess  in  thrombotic
complications  did  not  appear  to  result  from  a  “rebound”  hypercoagulability  but  was  rather  related  to  the  known
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challenges with initiating warfarin therapy after clinical trial completion [32, 33]. Accordingly, it  seems prudent to
consider  adequate  alternative  anticoagulation  coverage  during  planned  interruptions.  Nevertheless,  it  is  presently
unknown whether  bridging  anticoagulation  will  produce  a  net  clinical  benefit  and  which  approach  to  choose  [32].
Further clinical research and post marketing data analysis is needed to help clarify this critical issue. Until such data
becomes available it is important to counsel patients, minimize interruptions in therapy, and pay close attention to the
INR when transitioning to warfarin.
Comparison Among DOACs
There is no trial to date directly comparing DOACs. All DOACs provide equal or greater protection against all-
cause strokes as compared to dose adjusted warfarin, a benefit mainly driven by the reduction in hemorrhagic stroke [8,
11, 18, 20, 21] With reference to preventing ischemic stroke (Table 1), dabigatran appears to be more promising as
compared to warfarin in preventing ischemic strokes [8] but all other DOACs provide similar benefit in preventing
ischemic strokes in comparison to warfarin. All DOACs appear to have a more favorable safety profile compared to
warfarin in reducing bleeding complications including intracranial  hemorrhages though they are associated with an
increased risk for gastrointestinal hemorrhages [14, 18, 20] except for apixaban, which was shown to have similar risk
of gastrointestinal hemorrhage as warfarin in ARISTOTLE trial [11].
Table 1. Comparison of NOACs with Warfarin (Annual incidence rate).
Outcome
measures in
the clinical
Trials
RE-LY Rocket AF Aristotle Engage TIMI AF
Dabigatran
(150 mg
only)
Warfarin
RR (95%
CI)
Rivaroxaban Warfarin
HR (95%
CI)
Apixaban Warfarin
HR (95%
CI)
Edoxaban
(60 mg
only)
Warfarin
HR (95%
CI)
Composite of
strokes and
systemic
embolisms
1.11% 1.69% 0.66
(0.53-0.82)
1.70% 2.20% 0.79
(0.66-0.96)
1.27% 1.60% 0.79
(0.66-0.95)
1.18% 1.50% 0.87
(0.73-1.04)
Ischemic
strokes
0.92% 1.20% 0.76
(0.60-0.98)
1.34% 1.42% 0.94
(0.75-1.17)
0.97% 1.05% 0.92
(0.74-1.13)
1.25% 1.25% 1.00
(0.83-1.19)
Hemorrhagic
strokes
0.10% 0.38% 0.26
(0.14-0.49)
0.26% 0.44% 0.59
(0.37-0.93)
0.24% 0.47% 0.51
(0.35-0.75)
0.26% 0.47% 0.54
(0.38-0.77)
Intracranial
hemorrhages
0.30% 0.74% 0.40
(0.27-0.60)
0.50% 0.70% 0.67
(0.47-0.93)
0.33% 0.80% 0.42
(0.30-0.58)
0.39% 0.85% 0.47
(0.34-0.63)
Gastrointestinal
hemorrhages
1.51% 1.02% 1.50
(1.19-1.89)
3.20% 2.20% --* 0.76% 0.86% 0.89
(0.70-1.15)
1.51% 1.23% 1.23
(1.02-1.50)
All-cause
mortality
3.64% 4.13% 0.88
(0.77-1.00)
4.50% 4.90% 0.92
(0.82-1.03)
3.52% 3.94% 0.89
(0.80-0.99)
3.99% 4.35% 0.92
(0.83-1.01)
CI=confidence interval; HR=hazard ratio; RR=relative risk. *not provided.
REMAINING AREAS FOR CLARIFICATION
DOAC Use in the Elderly
DOACs ability of preventing stroke or systemic embolism as compared to warfarin was not dependent of patient’s
age but at the same time, greater reduction in the major bleeding complications noted in the younger (age <75 years)
patients as compared to elderly patients [16, 21]. For example, the risk of major extracranial hemorrhage increased with
dabigatran compared with warfarin with increasing age; nevertheless, the risk of intracranial bleeding remained lower in
the dabigatran arms [34]. Similarly, rivaroxaban is associated with an increased risk for non-major clinically relevant
bleeding in patients aged ≥75 years compared with warfarin [35]. Though, DOACs reduce all-cause stroke and systemic
embolism including in the elderly and do not appear to increase intracranial hemorrhages [16], further study of their
efficacy and safety particularly with respect to extracranial hemorrhages in the very old require further study.
Patients at Low Risk for Ischemic Stroke
The majority of patients included in the major trials comparing DOACs to warfarin included patients with moderate
to high risk for stroke (CHADS2 score >1). Though meta analysis of these trials did not show a significant difference
between risk groups, DOACs superiority over warfarin appeared to be driven by inclusion of patients at high stroke risk
(CHADS2 ≥3) [21]. Accordingly, warfarin remains a viable alternative to DOACs particularly among low risk subjects.
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Patients with Embolic Stroke of Undetermined Source
On  the  basis  of  the  apparent  low  hemorrhagic  risk  [8,  11,  18,  20,  21],  the  efficacy  and  safety  to  DOACs  for
secondary stroke prevention in patients with Embolic Stroke of Undetermined Source (ESUS) is being evaluated by two
ongoing  clinical  trials:  RE-SPECT ESUS compares  dabigatran  to  aspirin  [NCT02239120]  and  NAVIGATE ESUS
compares rivaroxaban to aspirin [NCT02313909].
Combination of DOACs with Antiplatelets
As per the American Heart Association Guidelines combination of anticoagulants and antiplatelet therapy is not
recommended  for  the  prevention  of  stroke  and  transient  ischemic  attack  but  may  be  reasonable  in  patients  with
clinically apparent coronary artery disease particularly acute coronary syndrome (Class IIb and level C evidence) [13].
In  the  subgroup  analysis  of  RE-LY,  concomitant  use  of  antiplatelets  was  associated  with  increased  risk  for  major
bleeding  complications  without  additional  benefits  of  preventing  ischemic  complications  [8].  In  time  dependent
analysis,  concomitant  use  of  a  single  antiplatelet  agent  and  dabigatran  (150  mg  twice  a  day)  was  associated  with
increased  risk  for  major  bleeding  complications  (HR  1.60,  95%  CI  1.42-1.82)  and  concomitant  use  of  double
antiplatelet agents further increased that risk (HR 2.31, 95% CI 1.79-2.98) [36]. Accordingly, combination therapy of
DOACs with antiplatelets should generally be avoided.
DOACs Management in the Perioperative Period
There are no specific guidelines regarding DOAC use in the perioperative period available at this time. As per the
manufacture  guidelines,  Dabigatran  should  be  discontinued  without  bridging  ranging  from  2  to  5  days  before  the
procedure depending upon renal function and risk of bleeding from procedure [37]. Rivaroxaban is recommended to be
discontinued for 24 hours before the invasive procedure and 36-48 hours before the surgery with high bleeding risk and
any surgery involving the central nervous system [38]. Apixaban should be discontinued for 24 hours before planned
surgery with low bleeding risk and for at least 48 hours before the moderate to high bleeding risk surgery or invasive
procedure [39].
Thrombolysis and Endovascular Therapy Decision Making in Acute Ischemic Stroke in Patients Treated with
DOACs
The increasing use of DOACs creates a challenge to acute ischemic stroke therapy with intravenous tissue-type
plasminogen activator (rtPA) in otherwise eligible patients [40, 41]. As previously discussed in this article, routine and
emergently available laboratory testing that reliably inform on anticoagulant effect in patients taking DOACs are not yet
available [31, 42]. While timing of the last dose of administration before hospital presentation could potentially help
determine the relative anticoagulant effect of DOACs it remains unknown whether this approach is safe. Accordingly,
routine administration of systemic rtPA in patients on DOACs is not recommended and great caution should be applied
when considering thrombolysis even if available conventional laboratory essays for anticoagulant activity (such as the
aPTT and INR) appear normal and time from last dose has been several hours [42]. Similarly, for patients presenting
with an acute large arterial occlusion endovascular stroke therapy may be considered [43, 44]; however, it should be
noted that none of the recent large randomized trials informed on safety and efficacy of endovascular stroke therapy in
patients on DOACs [45 - 49]. Thus, further clinical research is needed to clarify these important issues and therapeutic
decisions should be carefully weighted in each patient.
CONCLUSION
DOACs represent an appealing alternative to warfarin for the primary and secondary stroke prevention patients with
atrial fibrillation. DOACs as a group are more effective than dose adjusted warfarin for prevention of all-cause stroke
(including both ischemic and hemorrhagic stroke), and they have an overall more favorable safety profile. Nevertheless,
increased risk for gastrointestinal bleeding (with the exception of apixaban) and risk for thrombotic complication with
sudden discontinuation as well as inability to accurately assess anticoagulant efficacy and reverse the anticoagulant
effect require consideration prior to therapy initiation and pose a challenge for decision making in acute stroke therapy.
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